Current report No. 55/2021 – Expansion of the territorial scope of the licence agreement with Glenmark Pharmaceuticals Ltd.

Date prepared: December 16, 2021, time: 02:24 PM

Abbreviated name of the issuer: Celon Pharma S.A.

Subject: Expansion of the territorial scope of the licence agreement with Glenmark Pharmaceuticals Ltd.

Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information.

Content of the report:

In connection with current report No. 13/2021 K on Celon Pharma S.A. (“Company”) and Glenmark Pharmaceuticals Ltd with its registered seat in India concluding a licence agreement (“Agreement”) concerning cooperation in the registration, sale and distribution of a product that constitutes a combination of fluticasone and salmeterol in a dry powder inhaler (sold under the name Salmex in Poland), the Management Board of the Company hereby informs that an amendment to the aforementioned Agreement expanding its territorial scope to include Australia has been signed.

The amendment was concluded for a period of 10 years from the date of sales commencement in the given market, with the possibility of extension.